NASDAQ:TRAX First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis $46.56 -0.54 (-1.15%) Closing price 04:00 PM EasternExtended Trading$46.50 -0.06 (-0.13%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About First Tracks Biotherapeutics Stock (NASDAQ:TRAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TRAX alerts:Sign Up Key Stats Today's Range$46.28▼$48.4850-Day Range$30.59▼$52.3352-Week Range$14.72▼$54.78Volume438,193 shsAverage Volume718,417 shsMarket Capitalization$1.96 billionP/E RatioN/ADividend YieldN/APrice Target$72.17Consensus RatingModerate Buy Company Overview First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO. Read More First Tracks Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreTRAX MarketRank™: 3.581970482645 of 5 starsFirst Tracks Biotherapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 192nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingFirst Tracks Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialFirst Tracks Biotherapeutics has a consensus price target of $72.17, representing about 55.0% upside from its current price of $46.56.Amount of Analyst CoverageFirst Tracks Biotherapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about First Tracks Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for First Tracks Biotherapeutics are expected to grow in the coming year, from ($4.24) to ($3.80) per share.Price to Book Value per Share RatioFirst Tracks Biotherapeutics has a P/B Ratio of 12.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.03% of the float of First Tracks Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverFirst Tracks Biotherapeutics has a short interest ratio ("days to cover") of 6.52.Change versus previous monthShort interest in First Tracks Biotherapeutics has recently decreased by 27.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFirst Tracks Biotherapeutics does not currently pay a dividend.Dividend GrowthFirst Tracks Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.46 News SentimentFirst Tracks Biotherapeutics has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for First Tracks Biotherapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for TRAX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows3 people have added First Tracks Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, First Tracks Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,758,287.00 in company stock.Percentage Held by InstitutionsFirst Tracks Biotherapeutics has minimal institutional ownership at this time.Read more about First Tracks Biotherapeutics' insider trading history. Receive TRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for First Tracks Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRAX Stock News HeadlinesFirst Tracks Biotherapeutics (NASDAQ:TRAX) Reaches New 12-Month High After Strong EarningsNovember 6, 2026 | americanbankingnews.comFirst Tracks Biotherapeutics Q3 Loss Narrows As ANB033 Programs AdvanceNovember 4, 2026 | rttnews.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 16 at 1:00 AM | Behind the Markets (Ad)First Tracks Biotherapeutics Announces Participation in Upcoming Investor ConferencesNovember 3, 2026 | globenewswire.comFirst Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 3, 2026 | globenewswire.comFirst Tracks Biotherapeutics announces $200M private placementOctober 15, 2026 | msn.comFirst Tracks Biotherapeutics Announces $200 Million Private PlacementOctober 15, 2026 | globenewswire.comAnalysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX), Klarna Group Plc (KLAR) and Factset Research (FDS)October 14, 2026 | theglobeandmail.comSee More Headlines TRAX Stock Analysis - Frequently Asked Questions How have TRAX shares performed this year? First Tracks Biotherapeutics' stock was trading at $17.00 on April 21, 2026. Since then, TRAX shares have increased by 173.9% and is now trading at $46.56. How were First Tracks Biotherapeutics' earnings last quarter? First Tracks Biotherapeutics (NASDAQ:TRAX) announced its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.04. Who are First Tracks Biotherapeutics' major shareholders? Top institutional shareholders of First Tracks Biotherapeutics include State Street Corp (3.83%), Soleus Capital Management L.P. (0.33%), Marshall Wace LLP (0.21%) and HighVista Strategies LLC (0.17%). View institutional ownership trends. How do I buy shares of First Tracks Biotherapeutics? Shares of TRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/03/2026Today11/16/2026Jefferies Global Healthcare Conference11/16/2026UBS Global Biopharma Conference 202611/17/202638th Annual Healthcare Conference12/01/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TRAX CIK2091349 Webwww.firsttracksbio.com Phone858-362-6295FaxN/AEmployees104Year FoundedN/APrice Target and Rating Average Price Target for First Tracks Biotherapeutics$72.17 High Price Target$110.00 Low Price Target$31.00 Potential Upside/Downside+55.0%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.16 Quick Ratio9.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.59 per share Price / Book12.97Miscellaneous Outstanding Shares42,020,000Free FloatN/AMarket Cap$1.96 billion OptionableOptionable BetaN/A The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:TRAX) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Tracks Biotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share First Tracks Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.